On August 13, 2026, Aimed Alliance submitted comments to CMS regarding its proposed rule to codify the Medicare Drug Price Negotiation Program. While acknowledging its efforts to lower prescription drug costs, Aimed Alliance urged CMS to increase transparency and oversight to ensure negotiated drugs remain accessible to patients.
Specifically, Aimed Alliance called on CMS to publicly report aggregate data on formulary placement and utilization management practices, including prior authorization and step therapy requirements, for negotiated drugs. Aimed Alliance also urged CMS to closely monitor the program’s expansion to Medicare Part B and make aggregate trend data publicly available to help identify and address potential barriers to care. Greater transparency and oversight are essential to evaluating the Negotiation Program’s impact on beneficiary access and ensuring stakeholders can identify and address potential access concerns.
Read the Aimed Alliance’s Federal Drug Pricing Comment.
Last Updated on August 25, 2026 by Aimed Alliance
